scispace - formally typeset
F

F. Javier Oliver

Researcher at Spanish National Research Council

Publications -  44
Citations -  12770

F. Javier Oliver is an academic researcher from Spanish National Research Council. The author has contributed to research in topics: Poly ADP ribose polymerase & Autophagy. The author has an hindex of 23, co-authored 38 publications receiving 11056 citations. Previous affiliations of F. Javier Oliver include Carlos III Health Institute.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

PARP-1 is involved in autophagy induced by DNA damage.

TL;DR: It is suggested that autophagy might be cytoprotective during the response to DNA damage and suggest that PARP-1 activation is involved in the cell’s decision to undergoAutophagy.
Journal ArticleDOI

Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment

TL;DR: This is the first report of selective cell killing of HR-defective hypoxic cells in vivo as a consequence of microenvironment-mediated "contextual synthetic lethality" and may broaden the clinical utility of PARP and DNA repair inhibition, either alone or in combination with radiotherapy and chemotherapy, even in tumor cells lacking synthetically lethal, genetic mutations.